Formulary updates

July 2019

  • Following agreement of the Dapsone Specialised Medicines Service prescribing guideline in North and East Devon; the formulary entry has been updated with a link to the guideline.

June 2019

  • Kliniderm Superabsorbent dressings (10cm x 10cm, 10cm x 15cm, 20cm x 20cm, 20cm x 30cm, 20cm x 40cm) have been added as green (first line) options for patients with moderate to heavy exudating wounds that require a superabsorbent dressing. Click here for more information.
    • Eclypse dressings (10cm x 10cm, 15cm x 15cm, 20cm x 30cm, 60cm x 40cm) have been removed from the formulary
  • Cilique (ethinylestradiol 35micrograms/ norgestimate 250micrograms) tablets have been added to the formulary as a green (first line) option for hormonal contraception. Click here for more information.
  • Prontosan Debridement Pad has been added to the formulary as a green (first line) option for the soft mechanical debridement of wounds. Click here for more information.
    • DebriSoft Pad (10cm x 10cm) and DebriSoft Lolly (23.5cm x 10cm) have been removed from the formulary
  • Desmopressin oral lyophilisates 25micrograms & 50micrograms have been added to the formulary as an amber (specialist) option for primary idiopathic nocturnal polyuria in adults. Click here for more information.
  • Flexitol 25% Urea Heel Balm has been added to the formulary as an amber (specialist) option for the treatment of callused, anhidrotic, fissured, and hard foot skin conditions. Click here for more information.
  • International Dysphagia Diet Standardisation Initiative (IDDSI): A new way of describing texture modified foods and thickened liquids was introduced across the UK from April 2018 to April 2019. The new categorisation is called IDDSI and consists of a banding of eight levels (0 – 7) with consistency descriptors. The formulary has been updated to reflect this change. Please see the formulary for further guidance.
  • Neural tube defects (prevention in pregnancy): Guidance has been added for the prevention of neural tube defects in pregnancy and a link to guidance has been added to the folic acid drug entry. Please see the formulary for further guidance.
  • Liothyronine drug entry has been revised and updated to ensure consistency with local protocols for initiation and review of existing patients. Click here for more information.

May 2019

  • Commissioning Policy: The routine commissioning of semaglutide is accepted in Devon for patients with type 2 diabetes as described for glucagon-like peptide-1 (GLP-1) mimetics in NICE guideline NG28 (see Commissioning Policy for more details). Semaglutide has been added in the formulary as a green (first line) option in line with the policy. Click here for more information
  • Commissioning Policy: The routine commissioning of FreeStyle Libre is accepted in Devon for patients with diabetes mellitus in line with specific criteria (see Commissioning Policy for more details). Click here for more information

April 2019

  • Cilodex (ciprofloxacin 3mg/ml & dexamethasone 1mg/ml) ear drops, suspension has been added to formulary as a first line option for acute otitis externa (AOE) in adults and children over 1 year of age. Click here for more information.
  • Ganciclovir 0.15% eye gel has been added to the formulary as a first line option for acute herpetic keratitis. Click here for more information.
    • Aciclovir 3% eye ointment has been removed from the formulary due to product discontinuation
  • DEKAs Plus (liquid, chewable tablets, and softgels) and DEKAs Essential capsules have been added to the formulary as amber (specialist input) options for the dietary management of cystic fibrosis patients. Click here for more information.
  • Paravit-CF liquid has been added to the formulary as an amber (specialist input) option for the dietary management of cystic fibrosis in babies and patients with swallowing difficulties. Click here for more information.
  • Lyme disease: Formulary guidance has been revised and updated to provide more detail including specific antibiotic recommendations depending on the patient's age and presenting symptoms. Please see the formulary for further guidance.
  • Management of gout: Formulary guidance has been revised and updated. Please see the formulary for further guidance.
  • Prolongation of the QT interval: New guidance relating to drugs that prolong the QT interval has been developed and added to the cardiovascular chapter. Please see the formulary for further guidance.
  • Management of Secondary prevention of stroke and transient ischaemic attack (TIA): has been reviewed following the publication of The Exeter Guidelines for Secondary Prevention of Stroke and Transient Ischaemic Attack in Primary Care, 8th Edition, February 2019. Please see the formulary for further guidance.
  • Unipolar depression: NICE and Devon Partnership NHS Trust (DPT) prescribing guidelines have been used to revise and update formulary guidance. Please see the formulary for further guidance.

 

Home > Formulary > Updates > Recent Updates

 

  • First line
  • Second line
  • Specialist
  • Hospital